Andy Baker awarded the RSE Sir James Black Medal
REACT Co-director Professor Andy Baker has been awarded the Royal Society of Edinburgh (RSE) Sir James Black Medal, which recognises exceptional contributions to research across Scotland. Andy receives the award for his leading work in cardiovascular …
Events
We began offering REACT Masterclass sessions in April 2026 Lunchtime sessions on specific topics and techniques are tailored to members of the cardiovascular and gene therapy research communities. Our masterclasses will cover academic, clinical and …
Accessibility statement
This accessibility statement applies to AdvancedCardiacTherapies.ac.uk. This website is run by The University of Edinburgh. We want as many people as possible to be able to use this website. For example, that means you should be able to: change colours, …
Translation of genomics into routine cardiological practice: insights from a European Society of Cardiology Cardiovascular Round Table
Stefanie Dimmeler …
AAV6-based ZEB2 delivery promotes cardiomyocyte dedifferentiation in adult human myocardium
Rocco Caliandro …
Environmental sustainability
Each of our three principal partner institutions has developed ambitious sustainability strategies, underpinned by substantial investment and a shared commitment to climate action. As signatories to the Race to Zero for Universities and Colleges , they …
Cookie consent
AdvancedCardiacTherapies.ac.uk will set cookies on your device (either because they are necessary to make the site work and keep it secure, or if you give your consent). Cookies are small files that sit on your computer, phone or tablet. This information …
First annual symposium brings together growing REACT community
Members of the MRC/BHF CoRE in Advanced Cardiac Therapies (REACT) gathered in London last week for our first annual symposium. The meeting built on progress from our first year of operation and showcased the breadth of projects underway across the …
Clinical translation
A comprehensive array of pre-clinical models will be utilised to test therapeutic leads generated by REACT. Existing targets will be fast tracked for safety and efficacy assessment in models of chronic heart failure conditions, and then prioritised for …
Cardiac delivery
We aim to achieve cardiac-specific targeting of vectors and nanoparticle-delivered nucleic acid medicines to minimise adverse effects and allow for effective, inducible and/or regulated expression of single or multiple target therapeutic nucleic acids. …